Stay updated on Biomarker Response to Immunotherapy in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for a Phase 2 study of ipilimumab and nivolumab for advanced non-small cell lung cancer, rather than an access error. It includes the study’s terminated status and posted results alongside its design, eligibility, and treatment details.
    Difference
    51%
    Check dated 2026-11-07T12:34:20.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The displayed ClinicalTrials.gov revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-31T13:42:15.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition in terminology, stating that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-24T16:53:56.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-17T16:35:29.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The displayed ClinicalTrials.gov site revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T16:52:15.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    No textual changes were recorded for this page. The page currently displays a 403 Forbidden error, indicating access is blocked rather than content updates.
    Difference
    0.2%
    Check dated 2026-09-26T18:52:02.000Z thumbnail image

Stay in the know with updates to Biomarker Response to Immunotherapy in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page.